REVENUE (Tables)

6 Months Ended

Jun. 30, 2018

Revenue

Schedule of disaggregated revenue from contracts with customers

The following table summarizes revenue from contracts with customers for the three and six months ended June 30, 2018 and 2017 (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2018		2017		2018		2017
Product sales, net
Gralise	$	13,815	$	18,122	$	28,642	$	35,722
CAMBIA		8,089		8,495		14,505		15,685
Zipsor		3,988		4,403		8,734		9,054
Total neurology product sales, net		25,892		31,020		51,881		60,461
NUCYNTA products		626		63,938		18,771		120,857
Lazanda		320		5,274		540		9,199
Total product sales, net		26,838		100,232		71,192		190,517
Commercialization agreement:
Commercialization rights and facilitation services		31,179		—		59,274		—
Revenue from transfer of inventory		—		—		55,705		—
Royalties and Milestone Revenue		5,257		225		5,507		387
Total revenues	$	63,274	$	100,457	$	191,678	$	190,904

Summary of contract assets and liabilities

The following table presents changes in the Company’s contract assets and liabilities for the six months ended June 30, 2018 (in thousands):

	Balance						Balance
	as of						as of
	December 31. 2017		Additions		Deductions		June 30, 2018
Contract assets:
Contract asset - Collegium	$	—	$	55,705	$	(21,426)	$	34,279
Contract asset - Ironwood		—		5,000		—		5,000
		—		60,705		(21,426)		39,279